Media
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
Article featured in Health Affairs
MEDIA
Value creators or financial destroyers? The potential of gene therapies to transform healthcare
Article featured in STAT
New research brief: Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?
The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. However, the high treatment costs, budget impact, and unique challenges of SCD create a need for payment innovation to ensure access and sustainability for all stakeholders.
Webinar recap: How to tactically design a feasible outcomes-based contract in oncology
During the interactive discussion, the panel debated the various aspects of what a value-driven short-term milestone-based outcomes contract could look like, along with its challenges. Among them:
- The identification of usable metrics, such as discontinuation rates
- What data are relevant for the contract
- How and where to obtain the data used to evaluate the outcomes
- What party or parties are responsible for analysis of the data
- Whether the data are sufficient, and of sufficient quality, for the contract